Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/26/2020 11/27/2020 11/30/2020 12/01/2020 12/02/2020 Date
81.26(c) 81.06(c) 82.27(c) 81.37(c) 81.47 Last
4 271 277 4 712 696 15 489 196 8 323 527 571 583 Volume
+0.35% -0.25% +1.49% -1.09% +0.12% Change
More quotes
Financials (USD)
Sales 2020 49 435 M - -
Net income 2020 8 326 M - -
Net Debt 2020 19 268 M - -
P/E ratio 2020 24,6x
Yield 2020 3,49%
Sales 2021 52 515 M - -
Net income 2021 10 393 M - -
Net Debt 2021 14 725 M - -
P/E ratio 2021 19,3x
Yield 2021 3,63%
Capitalization 206 B 205 B -
EV / Sales 2020 4,55x
EV / Sales 2021 4,20x
Nbr of Employees 110 000
Free-Float 86,9%
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (79.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (20.5%; Sandoz). Net sales... 
Sector
Pharmaceuticals
Calendar
12/02Presentation
More about the company
Notations Surperformance© of Novartis AG
Trading Rating : Investor Rating :
More Ratings
All news about NOVARTIS AG
12/01NOVARTIS : Genentech Get Expanded FDA OK of Xolair for Nasal Polyps
DJ
11/29Swiss firms narrowly avoid 'Responsible Business' liability as vote divides n..
RE
11/27NOVARTIS AG : Barclays reaffirms its Sell rating
MD
11/26Business rights or human rights? Swiss vote shines spotlight on companies
RE
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/25NOVARTIS AG : Bryan Garnier maintains a Buy rating
MD
11/25NOVARTIS AG : UBS reiterates its Buy rating
MD
11/25NOVARTIS AG : Goldman Sachs remains its Buy rating
MD
11/24GLOBAL MARKETS LIVE: Tesla, Best Buy, Qantas…
11/24NOVARTIS AG : Goldman Sachs reaffirms its Buy rating
MD
11/24NOVARTIS : to Repurchase Up to $2.5 Billion in Shares
DJ
11/24NOVARTIS : starts share buyback, highlights product pipeline
RE
11/24NOVARTIS : highlights confidence in growing sales with margin expansion, fueled ..
AQ
11/20GLOBAL MARKETS LIVE: Pfizer, General Motors, Alphabet…
11/20NOVARTIS : New data at ASH to reinforce breadth of Novartis hematology portfolio..
AQ
More news
News in other languages on NOVARTIS AG
12/01MÄRKTE EUROPA/Anleger setzen auf den nächsten Aufschwung
12/01Bourse Zurich: dans le rouge pour la première séance du dernier mois de l'ann..
12/01Aktien Zürich Schluss: Börsenschwergewichte ziehen SMI leicht ins Minus
12/01Aktien Schweiz schließen etwas leichter - Defensive Werte drücken
12/01Bourse Zurich: le SMI retourne à l'équilibre
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 105,66 $
Last Close Price 90,44 $
Spread / Highest target 55,7%
Spread / Average Target 16,8%
Spread / Lowest Target -28,4%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-11.46%205 415
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
MERCK & CO., INC.-11.61%203 389
ABBVIE INC.18.12%184 633